肺动脉高压症状与影响问卷(PAH-SYMPACT)的心理测量学验证:SYMPHONY试验结果
本研究基于SYMPHONY试验(单臂、16周、马西替坦10mg、美国PAH患者)数据,对PAH-SYMPACT问卷进行内容定稿和心理测量学验证。最终问卷包含11个症状条目(心肺和心血管症状两个域)和11个影响条目(躯体与认知/情绪影响两个域)。各域内部一致性信度高(Cronbach's alpha > 0.80),稳定患者重测信度高(ICC 0.84-0.94),与参照问卷相关性中到高(r=0.34-0.80),能区分疾病严重程度并敏感反映改善。
要点
- PAH-SYMPACT含11个症状条目和11个影响条目,共四个域。
- 各域内部一致性信度高(Cronbach's alpha > 0.80),重测ICC 0.84-0.94。
- 问卷评分不受氧疗影响,能区分疾病严重程度并敏感反映改善。
核心结论
- PAH-SYMPACT是一种简短、疾病特异性的PRO工具,心理测量学属性良好,可用于临床实践和临床研究。
研究设计与样本
- 基于SYMPHONY试验(单臂、16周、马西替坦10 mg、美国PAH患者)的数据进行内容定稿和心理测量学验证。
- 共分析278例患者数据(79%女性;平均年龄60岁)。
主要发现
- 最终问卷包含11个症状条目(心肺和心血管症状两个域)和11个影响条目(躯体与认知/情绪影响两个域)。
- 所有四个域的Cronbach's alpha > 0.80,稳定患者ICC为0.84-0.94。
- 与CAMPHOR和SF-36的相关性为中等至高度(r=0.34-0.80)。
- 问卷能区分不同疾病严重程度患者,并对临床医生和患者报告的疾病严重程度改善敏感。
- differential item function分析确认PRO评分不受氧疗使用影响。
关键数值与推荐
- 内部一致性信度:Cronbach's alpha > 0.80(四个域)。
- 重测信度:ICC 0.84-0.94(稳定患者)。
- 与CAMPHOR和SF-36的相关性:r=0.34-0.80。
临床怎么用
- PAH-SYMPACT可用于临床实践中评估PAH症状和影响。
- 也可用于临床研究中的疗效评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is the first instrument for quantifying pulmonary arterial hypertension (PAH) symptoms and impacts developed according to the 2009 US Food and Drug Administration PRO guidance; previous qualitative research in patients with PAH supported its initial content validity. METHODS: Content finalization and psychometric validation were conducted by using data from A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT (SYMPHONY), a single-arm, 16-week trial with macitentan 10 mg in US patients with PAH. Item performance, Rasch analysis, and factor analyses were used to select the final item content of the PRO and to define its domain structure. Internal consistency, test-retest reliability, known-group and construct validity, sensitivity to change, and influence of oxygen on item performance were evaluated. RESULTS: Data from 278 patients (79% female; mean age: 60 years) were analyzed. Following removal of redundant/misfitting items, the final questionnaire has 11 symptom items across two domains (cardiopulmonary and cardiovascular symptoms) and 11 impact items across two domains (physical and cognitive/emotional impacts). Differential item function analysis confirmed that PRO scoring is unaffected by oxygen use. For all four domains, internal consistency reliability was high (Cronbach's alpha > 0.80), and scores were highly reproducible in stable patients (intraclass correlation coefficient: 0.84-0.94). Correlations with the Cambridge Pulmonary Hypertension Outcome Review questionnaire and the 36-item Medical Outcomes Study Short Form Survey were moderate to high ([r] = 0.34-0.80). The questionnaire differentiated well between patients with varying disease severity levels and was sensitive to improvements in clinician- and patient-reported disease severity. CONCLUSIONS: The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is a brief, disease-specific PRO instrument possessing good psychometric properties that can be administered in clinical practice and clinical studies. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01841762; URL: www.clinicaltrials.gov.
引用
- Chin KM, Gomberg-Maitland M, Channick RN, et al. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018. PMID: 29705220. doi:10.1016/j.chest.2018.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。